By Cheryl Guttman Krader; Reviewed by Jacob Brubaker, MD
Results from MERCURY-1, a 12-month phase III pivotal trial, show that once daily treatment with fixed-dose combination (FDC) netarsudil 0.02%/latanoprost 0.005% (Aerie Pharmaceuticals) is safe and provided significantly greater intraocular pressure (IOP)-lowering than either of its components throughout follow-up.
“Many patients cannot achieve their target IOP using a single topical medication, but a polypharmacy regimen reduces medication adherence that in turn can compromise eye health outcomes,” said Jacob Brubaker, MD, a MERCURY-1 study investigator and in private practice, Sacramento Eye Consultants, Sacramento, CA. “FDC products can simplify the treatment regimen, but those that are available in the United States require dosing two or three times daily, and none contain a prostaglandin analog.”
Dr. Brubaker pointed out that the efficacy and safety data from this phase III study are consistent with those of MERCURY-2, the second phase III study.
“Collectively, their data suggest that the FDC netarsudil/latanoprost may address an unmet need for an FDC that provides greater efficacy than the prostaglandin analogs with a reduced treatment burden compared with current options,” he added.